Literature DB >> 22726962

Frequency and etiology of unexplained bilateral hydronephrosis in patients with breast cancer: results of a longitudinal CT study.

Ari J Kane1, Zhen J Wang, Aliya Qayyum, Benjamin M Yeh, Emily M Webb, Fergus V Coakley.   

Abstract

We retrospectively reviewed the records of 153 patients with breast cancer undergoing serial abdominal computed tomography (CT). During a median follow-up of 40 months, 2 (1.4%) of 153 patients developed bilateral hydronephrosis in the absence of radiologically visible obstructing pathology. Surgery confirmed malignant infiltration of the ureters by metastatic lobular carcinoma in both patients, suggesting that new unexplained bilateral hydronephrosis on serial CT in patients with breast cancer is likely to reflect infiltrative retroperitoneal involvement of the ureters by metastatic lobular carcinoma.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22726962     DOI: 10.1016/j.clinimag.2011.10.001

Source DB:  PubMed          Journal:  Clin Imaging        ISSN: 0899-7071            Impact factor:   1.605


  3 in total

1.  Comparison of 18F-FDG PET/CT for Systemic Staging of Newly Diagnosed Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma.

Authors:  Molly P Hogan; Debra A Goldman; Brittany Dashevsky; Christopher C Riedl; Mithat Gönen; Joseph R Osborne; Maxine Jochelson; Clifford Hudis; Monica Morrow; Gary A Ulaner
Journal:  J Nucl Med       Date:  2015-08-20       Impact factor: 10.057

2.  Head-to-Head Evaluation of 18F-FES and 18F-FDG PET/CT in Metastatic Invasive Lobular Breast Cancer.

Authors:  Gary A Ulaner; Komal Jhaveri; Sarat Chandarlapaty; Vaios Hatzoglou; Christopher C Riedl; Jason S Lewis; Audrey Mauguen
Journal:  J Nucl Med       Date:  2020-07-17       Impact factor: 10.057

3.  Retroperitoneal fibrosis secondary to non-urology carcinomas: a clinical and outcome analysis of 97 cases.

Authors:  T Chen; L Tian; D Fan; F Wu; J Lu; S Ding
Journal:  Clin Transl Oncol       Date:  2018-09-04       Impact factor: 3.405

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.